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Ability of Primary Care Health Databases to 
Assess Medicinal Products Discussed by 
the European Union Pharmacovigilance Risk 
Assessment Committee
Robert Flynn1,2,* , Karin Hedenmalm1 , Tarita Murray-Thomas3, Alexandra Pacurariu1 ,  
Peter Arlett1 , Hilary Shepherd3, Puja Myles3  and Xavier Kurz1
This study measured the exposure to different categories of medicinal products discussed by the European 
Union (EU) Pharmacovigilance Risk Assessment Committee from September to November 2018 in four electronic 
primary care health databases: IQVIA Medical Research Data-UK, IQVIA Medical Research Data-France, IQVIA 
Medical Research Data-Germany, and Clinical Practice Research Datalink Aurum, in the entire lifespan of each 
database until August 31, 2018. The assessment of 83 centrally authorized products and 45 nationally authorized 
products showed that coverage was better for products marketed for longer duration and worse for orphan drugs. 
The ability to detect associations against hypothetical comparators was better for more common events and for 
larger effect sizes. Coverage of advanced therapies was worse for those typically administered in a specialized rather 
than primary care setting. This study shows that to enable better informed regulatory decisions there is a need to 
access complementary data sources, particularly capturing secondary care prescribing.
The European Union (EU)’s pharmacovigilance system has at its 
core the European Medicines Agency (EMA)’s Pharmacovigilance 
Risk Assessment Committee (PRAC) with the responsibility to 
protect patients by ensuring that the safety of medicines on the 
market are under continual review. This task includes the detec-
tion and assessment of the risk of adverse reactions, while taking 
the therapeutic effect of the medicine into account.1,2 The EU 
pharmacovigilance system is, therefore, underpinned by scientific 
evaluation of all the evidence available, including valid data on the 
utilization and effects of medicines in clinical practice.
The EMA supports medicines evaluation by analyzing data for 
products or groups of products, particularly where it is hard to iden-
tify a single marketing authorization holder from three commer-
cially available electronic primary care health databases (primary 
EHDs) that it accesses to assess drug utilization, risks of medicines, 
and effectiveness of risk minimization measures.3–9 These primary 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Electronic primary care health databases are used by regula-
tors to assess the need for and the impact of postlicensing regu-
latory interventions.
WHAT QUESTION DID THIS STUDY ADDRESS?
 We measured the extent to which exposure to different cat-
egories of medication was covered in the electronic primary care 
health databases available to the European Medicines Agency.
WHAT DOES THIS STUDY ADD TO OUR KNOW - 
LEDGE?
 More advanced and more recently authorized medicinal 
products had less coverage in the available databases compared 
to more established, nationally licensed products.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 To optimize the regulatory decision-making process regula-
tors need better access to data that allows the postlicensing as-
sessment of newer, more advanced therapies. This study shows 
that many such therapies are not used in the primary care set-
ting and regulators should seek to gain access to complementary 
data sources, particularly those capturing the use of medicines 
in specialist settings.
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EHDs include routinely collected patient data from a network or 
a sample of mainly general practitioners (GPs) practices. Primary 
EHDs represent an optimal data source for medicines evaluation 
by capturing detailed information on patients’ health status, drugs 
prescribed, and medical outcomes. In addition, their large size 
may allow the study of rare events and their representativeness of 
routine clinical care may allow the study of real-world effects of 
medicines prescribed in the community. Due to their retrospective 
nature, they can also be analyzed rapidly.10
A previous study has reported that some drug exposures may be 
incompletely captured in primary EHDs because they are utilized 
only in secondary care (hospital) settings or in specialized insti-
tutions or because they are not reimbursed.11 For the EMA, this 
limitation would be relevant in light of its responsibility for the 
authorization and monitoring of centrally authorized products 
(CAPs) in the European Union. The centralized procedure is com-
pulsory for medicine used to treat specific conditions (for example, 
HIV/AIDS, diabetes, and neurodegenerative diseases), medicines 
derived from biotechnology processes, advanced-therapy medi-
cines (for example, gene therapies), and orphan medicines (for rare 
diseases) and is optional for other medicines that are significant 
innovations or which are of public health interest. In practice, this 
means that the majority of new medicines pass through the cen-
tralized authorization procedure, which infers EU-wide marketing 
authorization. In 2018, 84 medicines were recommended for ap-
proval by the EMA and for 58 of them (69.0%) the product infor-
mation recommended initiation and supervision of the treatment 
by a specialist.12 This feature may increase over time given the high 
number of marketing authorization applications for advanced ther-
apy medicinal products (ATMPs—a class of products that include 
gene therapies, tissue engineered products, and somatic cell thera-
pies) expected in the next few years. During January 2009 to June 
2018, the EMA received a total of 564 requests relating to ATMPs: 
286 requests for ATMP classification and 278 for scientific advice 
for these products.13 Detailed information on prescriptions from 
secondary care in primary care databases, therefore, requires that 
patients from secondary care are routinely followed up in primary 
care, like in the United Kingdom, and that prescribing information 
from secondary care is shared with primary care and recorded in 
the patients’ electronic records.
Empirical observations during PRAC meetings have shown that 
several products discussed by PRAC have limited or no exposure 
readily available in the primary EHDs available to the EMA and 
that complementary data sources would be needed for their assess-
ment, such as claims data or patient registries.14 If true, these obser-
vations would need to be considered by the EU pharmacovigilance 
system as regard to the type, characteristics, and complementary 
nature of data sources to be used to support the evaluations, and 
the data checks to be applied when planning studies. This issue also 
concerns marketing authorization holders, which may be required 
to provide additional data in the course of PRAC assessments.2
This evaluation was undertaken to systematically measure the 
exposure to prescribing for medicinal products included in topics 
discussed by the PRAC in primary EHDs and to identify charac-
teristics associated with the exposure prevalence, such as type of 
authorization (at European level for CAPs or at the national level 
for nationally authorized products (NAPs)), duration of authoriza-
tion, and therapeutic class. Four available primary EHDs were used 
for the study: IQVIA Medical Research Data-France (IMRD-
France, formerly IMS-France), IQVIA Medical Research Data-
Germany (IMRD-Germany, formerly IMS-Germany), IQVIA 
Medical Research Data-United Kingdom (IMRD-UK, incorpo-
rating data from THIN, a Cegedim Database), and the Clinical 
Practice Research Datalink (CPRD).
METHODS
Drug substances
We extracted from the time schedule of the PRAC plenary meetings of 
September, October, and November 2018, all substances or classes of 
substances included in regulatory procedures, except those related to 
risk management plans concerning products in the preauthorization 
phase (where no real-world data would be available prior to  marketing), 
inspections, and organizational matters, which are not specific to au-
thorized products.15 This period was chosen to allow availability of 
contemporaneous data to the PRAC meetings. Taking 3  months in 
a row decreased the likelihood of duplication of substances given the 
time needed to collect and analyze additional information in the case of 
 follow-up actions.
Primary electronic healthcare databases
As a first step in the analysis, we assessed the prescription counts for each 
country involved in the analysis: For England (digital.nhs.uk), for France 
(ameli.fr), and for Germany (wido.de). This information served as a back-
ground for consistency checks and was useful to clarify why some drugs 
were not represented in our databases. We then searched for drug expo-
sure to each substance or class of substances in four electronic primary 
EHDs: IQVIA Medical Research Data-France (IMRD-France), IQVIA 
Medical Research Data-Germany (IMRD-Germany), IQVIA Medical 
Research Data-United Kingdom incorporating data from THIN, a 
Cegedim Database (IMRD-UK), and the Clinical Practice Research 
Datalink (CPRD) Aurum database. The three IMRD databases are con-
tractually available to the EMA in-house.
IMRD-France collects anonymized electronic health records through 
a panel of GPs representing about 2% of physicians, weighted by age and 
sex of the physician, doctor region, and an indicator of the GP’s volume of 
activity in terms of visits and consultations. In France, patients can visit a 
physician of choice whenever a medical need emerges, although they must 
visit a GP before going to a specialist in order to get reimbursement, except 
for pediatricians, gynecologists, and ophthalmologists. The coding system 
for medicinal products is based on the European Pharmaceutical Market 
Research Association (EphMRA). A drug dictionary with unique identifi-
ers for each drug is provided with the database.
IMRD-Germany collects anonymized electron health records (EHRs) 
through a representative panel of GPs, some specialists in internal medi-
cine, and other specialist physicians (~ 3% of all GPs in Germany), strat-
ified for specialist group, region, community size, and age of physician. 
In Germany, patients can visit a physician of choice, including a special-
ist physician, whenever a medical need emerges. Parents often choose 
to consult a pediatrician directly for the health care of their child. The 
coding system and search method for medicinal products are similar to 
IMRD-France, but the drug dictionary is more detailed allowing for iden-
tification of originator/generic products and parallel imported products.
In the United Kingdom, GPs play a gatekeeper role in the healthcare 
system, as they are responsible for delivering primary health care and spe-
cialist referrals. Over 98% of the UK-resident population is registered with 
a GP, so that GP patient records are broadly representative of the UK pop-
ulation in general. Patients are affiliated to a practice, which centralizes 
the medical information from GPs, specialist referrals, hospitalizations, 
and tests.
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IMRD-UK contains longitudinal electronic patient records ex-
tracted from the VISION practice management software, which 
has been contributed to by >  790 general practices across the United 
Kingdom covering ~  6% of the UK population. Data are largely rep-
resentative of the UK population in terms of age, sex, deprivation 
status, and geographic distribution. It contains GP prescriptions with 
medicinal products identified through a bespoke system of drug codes 
linked to generic drug names (substance names) or a substitute thereof 
in a drug and device dictionary. This dictionary is provided with the 
database.
Clinical Practice Research Datalink (CPRD) comprises anonymized 
computerized medical records of GPs from a UK-wide network of over 
1,100 primary care practices covering about 15% of the population in 
August 2019. The CPRD comprises two complementary databases—
CPRD GOLD (data collected from practices using VISION practice 
management software) and CPRD Aurum (data collected from prac-
tices using EMIS practice management software). As practices in CPRD 
GOLD and IMRD-UK overlap, analyses were restricted to CPRD 
Aurum practices. To further minimize the possibility of overlap between 
IMRD-UK data and CPRD Aurum, CPRD Aurum practices known to 
have switched from using Vision Practice Management software were also 
excluded. A total of 721 EMIS practices comprising of over 18 million 
patients were eligible for inclusion in the analysis. Drugs in the CPRD 
Aurum database are coded using the National Health System (NHS) dic-
tionary of medicines and devices codes, and EMIS system-specific codes. 
Therapy code lists and medical codes, where applicable, were developed 
for this study using searches based on the drug substance, product name, 
and term in the CPRD Aurum product dictionary, and using Read codes 
and Read terms in the medical dictionary.
Data extraction
The following information was extracted from the PRAC time 
schedule: Month of PRAC meeting, regulatory procedure where 
the substance was included, substance name or class of substances, 
authorization type (CAP or NAP) of each substance, and product 
name for CAPs. If both authorization types existed for the same 
substance, the substance was classified as CAP. In cases where a drug 
class contained both CAPs and NAPs, the classification was based 
on the authorization type of the majority of substances. Drug classes 
“Fluoroquinolones,” “Selective serotonin reuptake inhibitors,” and 
“Hormonal contraceptives” were classified as NAPs and the class 
“Serotonin and noradrenaline reuptake inhibitors” was classified as 
CAP. For CAPs, information on authorization date in the European 
Union and orphan designation status (substance indicated for a con-
dition with prevalence not higher than 5/10,000 in the European 
Union) was extracted from the EMA website; for NAPs, information 
on authorization status in the United Kingdom, France, and Germany 
and the date of first authorization in the European Union was ex-
tracted from public and nonpublic data from the EMA’s Article 57 
database.16 In order to verify the marketing status of each substance, 
publicly available prescription or sales data in primary care were con-
sulted for each country.17–19 The therapeutic class for each substance 
was assigned based on the Anatomic Therapeutic Chemical (ATC) 
classification.20
Estimation of drug exposure
For each substance (or class of substances), the number of prescrip-
tions and the number of patients receiving at least one prescription 
was searched during the entire lifespan of each database until August 
31, 2018. For substances existing both alone and in combination, the 
search was made either for the individual component or for the com-
bination, in line with the information provided in the PRAC time 
schedule. There was no restriction with regard to duration of fol-
low-up, number of prescriptions, duration of prescriptions, or gaps be-
tween prescriptions. Prescriptions with missing dates were excluded. 
More than one prescription for the same substance on the same day 
counted as a single prescription. The end of observation for each pa-
tient was defined as the earliest of the patient transfer out date, the 
practice last collection date and the of August 31, 2018 (end of the 
evaluation period). All patients were required to have at least one day 
of follow-up on or before August 31, 2018.
Data analysis
Descriptive analyses include the number of substances without any 
prescription per database, authorization type and duration of autho-
rization in three categories (< 2 years, 2–5 years, and > 5 years), and 
the median (with range) number of prescriptions and patients avail-
able per database, authorization type, and duration of authorization. 
The same statistics were calculated for the pooled data from each 
database.
To estimate the number of substances for which each database could 
meaningfully assess adverse events, we calculated the numbers of patient 
exposures required to detect a statistically significant adverse event associ-
ated with a range of theoretical relative risks (RRs) for CAPs and NAPs in 
different frequency categories. This was based on a hypothetical compari-
son of two proportions using a two-sided Fisher exact test with α = 0.05, 
power = 0.90 and equal numbers of patients exposed to the drug of inter-
est and a comparator. Effect sizes of a doubling and a four-times increase 
in events rate against a hypothetical comparator were used. Adverse event 
rates were based on the Summary of Product Characteristics adverse drug 
reaction frequencies and were conservatively taken from the least common 
end of the frequency ranges: 1 of 10 for “very common,” 1 of 100 for “com-
mon,” 1 of 1000 for “uncommon,” 1 of 10,000 for “rare,” and 1 of 100,000 
for “very rare.”
RESULTS
A total of 128 drug substances or substance classes were extracted 
from the topics listed in the time schedules of the PRAC meetings 
for September, October, and November 2018, including 83 CAPs 
(64.8%) and 45 NAPs (35.2%); 51 substances (39.8%) were discussed 
in the context of assessments of periodic safety update reports and 
31 substances (24.2%) in the context of assessments of safety signals 
(Table 1). The most frequently discussed substances were antineo-
plastic agents or immunomodulators for CAPs (36.1%) and those 
indicated for the nervous system for NAPs (28.9%). The list of sub-
stances with their characteristics is provided in the Supplementary 
Table. Among the NAPs, four substances discussed by PRAC were 
Table 1 Number of substances extracted from PRAC time 
schedules for September, October, and November 2018 by 
regulatory procedure15 and authorization type
Regulatory procedure CAPs NAPs Total
PASS protocol or results 7 3 10
PSUR 28 23 51
Referral 2 0 2
Renewal or reassessment 4 0 4
Request for advice 4 10 14
RMP postauthorization 10 0 10
Safety signal 28 9 37
Total 83 45 128
CAPs, centrally authorized products; NAPs, nationally authorized products; 
PASS, postauthorization safety study; PSUR, periodic safety update report; 
RMP, risk management plan.
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not authorized in the United Kingdom, France, or Germany, two 
were authorized in France only, and one each were authorized only 
in the United Kingdom and Germany. Among CAPs, 6 (7.2%) had 
been authorized for < 2 years on September 1, 2018, 20 (24.1%) had 
been authorized for 2–5 years, and 57 (68.7%) had been authorized 
for > 5 years (Table 2). Where marketed, all NAPs had been na-
tionally authorized for > 5 years.
There was some variability among the four databases in the per-
centages of substances with at least one prescription in primary care 
(Table 2). For all CAPs, it was 59.0% in IMRD-France, 89.2% in 
IMRD-Germany, 78.3% in IMRD-UK, and 86.7% in CPRD 
Aurum; in all cases, the proportion increased with increasing du-
ration of authorization. For NAPs, the percentages were 73.3%, 
86.7%, 75.6%, and 77.8%, respectively. The higher percentages in 
Germany are not explained by the inclusion in the German data-
base of patients consulting primary care specialists as opposed to 
GPs as only one substance not prescribed by GPs was prescribed 
by specialists and that was used in four patients only. Broadly, there 
Table 2 Number and percentage of CAP and NAP substances (or classes of substances) with at least one prescription, 
median (IQR) number of prescriptions, and median (IQR) number of patients per authorization type and duration of 
authoriation for CAPsa 
 
CAPs
NAPs
Duration of authorization 
(years)
< 2 2–5 > 5 All
All substances, n 6 20 57 83 45
IMRD-France
n (%) substances with 
≥ 1 prescription
1  
(16.7)
10 
(50.0)
38 
(66.7)
49 
(59.0)
33 
(73.3)
Median (IQR) of 
prescriptions
0 
(0–0)
1 
(0–77)
74 
(0–7,413)
15 
(0–5,069)
6,709 
(0–127,953)
Median (IQR) of patients 0 
(0–0)
1 
(0–40)
32 
(0–2,320)
14 
(0–1,477)
4,074 
(0–32,701)
IMRD-Germany
n (%) substances with 
≥ 1 prescription
4 
(66.7)
17 
(85.0)
53 
(93.0)
74 
(89.2)
39 
(86.7)
Median (IQR) of 
prescriptions
174 
(0–709)
536 
(69–5,307)
16,127 
(1,354–127,467)
6,204 
(343–69,411)
103,577 
(181–585,347)
Median (IQR) of patients 34.5 
(0–140)
168.5 
(15–1,458)
2,339 
(239–31,533)
1,219 
(60–18,934)
15,973 
(84–208,522)
IMRD-UK
n (%) substance  
with ≥ 1 prescription
3 
(50.0)
15 
(75.0)
47 
(82.5)
65 
(78.3)
34 
(75.6)
Median 
(IQR)—prescriptions
0.5 
(0–2)
22 
(1–941)
846 
(16–246,318)
100 
(1–65,081)
129,419 
(7–2,059,555)
Median (IQR)—patients 0.5 
(0–2)
15.5 
(1–179)
245.0 
(7–9,906)
67 
(1–4,363)
8,528 
(7–202,276)
CPRD Aurum
n (%) substances with 
> 1 prescription
3 
(50.0)
19 
(95.0)
50 
(87.7)
72 
(86.7)
35 
(77.8)
Median (IQR) of 
prescriptions
1 
(0–10)
126.5 
(18–1,627)
1,611 
(43–200,183)
460 
(12–83,560)
179,339 
(15–2,405,014)
Median (IQR) of patients 0.5 
(0–9)
121.5 
(17–483)
499 
(33–11,315)
345 
(11–7,265)
10,690 
(10–250,170)
Pooled data
n (%) substances with 
> 1 prescription
4 
(66.7)
20 
(100)
54 
(94.7)
78 
(94.0)
42 
(93.3)
Median (IQR) of 
prescriptions
179.5 
(0–713)
1,038.5 
(97–15,526)
36,112 
(3,629–749,636)
9,133 
(402–237,749)
582,925 
(13,583–5,357,804)
Median (IQR) of patients 39.5 
(0–143)
573 
(35–2,460)
5,616 
(420–70,195)
1,657 
(93–38,867)
249,422 
(3,010–780,308)
CAPs, centrally authorized products; CPRD, Clinical Practice Research Datalink; IMRD, IQVIA Medical Research Data; IQR, interquartile range; NAPs, nationally 
authorized products.
aAll NAPs were authorized for > 5 years.
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was consistency between the two UK data sources, which shared 
11 CAPs and 10 NAPs that had no patient exposure in both data 
sources.
The number of CAP substances with at least one prescription, 
the median number of patients with a prescription, and the me-
dian number of prescriptions increased by duration of authori-
zation, although the numbers are low for CAPs with < 2 years of 
authorization (Table 2). A characterization of substances with 
no prescribing is shown in Table 3 for each database. Factors 
associated with nonprescribed drugs varied by country, for ex-
ample, with reimbursement being a determining factor in France 
and the number of many “hospital only” drugs in the UK data-
bases. Overall, the IMRD-Germany data had the lowest level of 
nonuse.
Ten CAPs were orphan medicinal products of which five 
were antineoplastic agents. Across all databases, just 2 of 10 or-
phan medicinal products had no patients exposed; however, the 
pooled number of patients exposed for each database was low, 
with a maximum of 143 patients being exposed across all data 
sources and 6 of the 10 orphan medicinal products having < 10 
patients exposed.
Tables 4 and 5 show the ability of the databases to detect 
significantly different event rates for effects of various sizes in a 
hypothetical comparison with an equal number of comparator 
patients.
None of the individual databases would be able to detect a dou-
bling in effect size for the majority of CAPs (Table 4) for “com-
mon,” “uncommon,” “rare,”or “very rare” events, or NAPs (Table 5) 
for “uncommon,” “rare,” or “very rare” events. Where the effect size 
was greater, with a four times increased risk, the ability to detect a 
statistically significant difference was also greater, but still only cov-
ered a minority of CAPs for “uncommon,” “rare,” and “very rare” 
events, and “rare” and “very rare” events for NAPs.
An analysis of the pooled data, where the numbers of patients ex-
posed from each data source were combined, would allow the detec-
tion of an “uncommon” adverse event associated with a doubling of 
risk in 26.5% of CAPs and 60.0% of NAPs. For events that were “rare” 
or “very rare,” the proportion of CAPs would be much lower (4.8% 
and 0%, respectively, for the CAPs; 40.0% and 11.1% for NAPs). 
For a larger effect size, where the hypothetical increase in events rate 
was fourfold, the ability to detect statistically significant differences 
was greater for “uncommon” events (38.6% of CAPs, and 71.1% of 
NAPs). However, this remained low for “rare” and “very rare” events 
with only a minority of associations being meaningfully tested (19.3% 
and 3.6%, respectively, for CAPs, and 57.8% and 28.9% for NAPs).
DISCUSSION
Multiple potential sources of data may be used in the regulatory 
decision making, including EHRs generated in both the primary 
and secondary care environments, administrative claims records, 
prescription event monitoring systems, prescription databases, and 
registries. Clinical information from these other sources may be used 
to complement data already available and to more effectively moni-
tor the safety and efficacy of authorized medicines once marketed.2 
However, each of these data sources has strengths and limitations 
associated with its use and a clear understanding of these is essential 
to define where and when each data source can add the most value.
A recent descriptive analysis of the utility of EHDs for regula-
tory purposes found that 34 EHDs were relevant based on data 
availability for both drug exposure and outcomes, but this did not 
consider actual availability or prevalence of medicinal products.21 
Similarly, guidelines aiming to assist in the selection and use of data 
resources in pharmacoepidemiology recommend obtaining a thor-
ough knowledge of the unique characteristics of each data source, 
Table 3 Characterization of CAP and NAP substances with 
zero patient counts
IMRD-France
34 CAPs
16 not actively marketed
6 oncologic (most likely hospital only)
12 restricted use (e.g., only reimbursed for in-hospital use)
12 NAPs
5 unlicensed or not actively marketed
7 not reimbursed or restricted use (e.g., only reimbursed for 
in-hospital use)
IMRD-Germany
9 CAPs
3 not actively marketed
3 oncologic (most likely hospital only)
2 for rare/orphaned conditions (likely only to be used in a 
specialized setting)
1 hospital only drug
6 NAPs
3 unlicensed or not actively marketed
3 likely to be used in hospital or specialized settings only
IMRD-UK
18 CAPs
4 not actively marketed
7 oncologic
4 for rare/orphaned conditions
3 unlikely to be used in the primary care
11 NAPs
5 unlicensed or not actively marketed
6 unlikely to be used in the primary care
CPRD Aurum
11 CAPs
4 not actively marketed
3 oncologic (most likely hospital only)
1 for rare/orphaned conditions
3 unlikely to be used in the primary care
10 NAPs
5 unlicensed or not actively marketed
5 unlikely to be used in the primary care
 
CAPs, centrally authorized products; CPRD, Clinical Practice Research 
Datalink; IMRD, IQVIA Medical Research Data; NAPs, nationally authorized 
products.
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but not to go beyond general recommendations in terms of evalua-
tion of exposure to medicinal products.10,22,23
Our analysis has shown large differences among the four databases 
in the availability of CAPs and NAPs (as identified from substances 
with at least one prescription) and the number of patients represent-
ing the population for a potential drug utilization or outcome study. 
The German data covered a wider array of medicinal products than 
the other data sources. This probably reflects the fact that in Germany 
there are fewer restrictions on what can be prescribed by GPs. In ad-
dition, the German data include prescriptions that are reimbursed via 
private insurance schemes, potentially including a wider selection of 
drugs. Overall, the ability to study CAPs authorized for < 2 years is 
limited but the experience of 3 months of PRAC meetings has shown 
that only six recent substances (of 128 in total) were discussed by the 
PRAC over the 3-month period. Although we looked at all medicines 
discussed at PRAC over a 3-month period, it should be noted that 
there was a potential role for the analysis of EHR analysis in supporting 
PRAC decision making in only a minority of cases. However, the pur-
pose of our analysis was to establish the applicability of available data 
to the sorts of drug that are, in general, discussed at PRAC, rather than 
to imply that each of the medicines listed required additional analysis.
The use of EHDs seems able to address safety concerns for 
most medicines if the adverse event of interest is in the common 
or very common categories. Adverse events of such frequencies 
may already be well characterized by prelicensing and postlicens-
ing randomized trials, and the role of EHRs to provide further 
data may be limited to addressing the frequency and character-
istics of events in real-world use. It is for adverse events that are 
less common (those that are uncommon, rare, or very rare in fre-
quency), or adverse events that only appear after long-term treat-
ment or which have a long latency period, where primary EHDs 
would be most informative. We found that for CAPs in partic-
ular, only a minority of medicinal substances being discussed by 
the PRACs had sufficient data to allow meaningful comparison 
of event rates between the exposure of interest and a comparator 
cohort. As might be expected for primary care databases, cover-
age was lower for medicinal products that were more likely to 
be used in a secondary or tertiary care setting. Primary EHDs 
are key data sources to provide information on use and effects of 
medicines in routine clinical practice, but our study highlights 
the need for regulators to supplement them with data sources 
that include medicines used prescribed in specialized settings.
The relevance of a database for particular research depends on 
the question to be addressed. Exploring this Coloma et al. used 
data from eight European databases to determine the amount 
of drug exposure required for signal detection across varying 
Table 4 Number and percentages of CAP substances discussed by PRAC (n = 83) for which a causal association with a 
suspected ADR could be investigated according to different background rates and strengths of association
Background 
risk Association with RR of 2.0 Association of RR of 4.0
(per number 
of patients)
Requireda number 
of patients exposed
No (%:95% confidence interval) of 
substances that can be investigated
Requireda number 
of patients exposed
No (%:95% confidence interval) of 
substances that can be investigated
Very common 
≥(1/10)
282 FR: 25 (30.1: 21.3–40.7)
DE: 51 (61.4: 50.7–71.2)
UKTh: 33 (39.8: 29.9–50.5)
UKCP: 42 (50.6: 40.1–61.1)
All: 56 (67.5: 56.8–76.6)
47 FR: 32 (38.6: 28.8–49.3)
DE: 65 (78.3: 68.3–85.8)
UKTh: 45 (54.2: 43.6–64.5)
UKCP: 56 (67.5: 56.8–76.6)
All: 68 (81.9: 72.3–88.7)
Common 
(1/100)
3,220 FR: 15 (18.1: 11.3–27.7)
DE: 30 (36.1: 26.6–46.9)
UKTh: 25 (30.1: 21.3–40.7)
UKCP: 28 (33.7: 24.5–44.4)
All: 37 (44.6: 34.4–55.3)
585 FR: 23 (27.7: 19.2–38.2)
DE: 47 (56.6: 45.9–66.8)
UKTh: 30 (36.1: 26.6–46.9)
UKCP: 33 (39.8: 29.9–50.5)
All: 52 (62.7: 51.9–72.3)
Uncommon 
(1/1,000)
32,601 FR: 2 (2.4: 0.7–8.4)
DE: 14 (16.9: 10.3–26.3)
UKTh: 12 (14.5: 8.5–23.6)
UKCP: 14 (16.9: 10.3–26.3)
All: 22 (26.5: 18.2–36.9)
5,960 FR: 12 (14.5: 8.5–23.6)
DE: 29 (34.9: 25.6–45.7)
UKTh: 19 (22.9: 15.2–33.0)
UKCP: 24 (28.9: 20.3–39.4)
All: 32 (38.6: 28.8–49.3)
Rare 
(1/10,000)
326,417 FR: 0 (0.0: 0.0–4.4)
DE: 0 (0.0: 0.0–4.4)
UKTh: 1 (1.2: 0.2–6.5)
UKCP: 1 (1.2: 0.2–6.5)
All: 4 (4.8: 1.9–11.7)
59,708 FR: 2 (2.4: 0.7–8.4)
DE: 10 (12.0: 6.7–20.8)
UKTh: 8 (9.6: 5.0–17.9)
UKCP: 9 (10.8: 5.8–19.3)
All: 16 (19.3: 12.2–29.0)
Very rare 
(1/100,000)
3,264,571 FR: 0 (0.0: 0.0–4.4)
DE: 0 (0.0: 0.0–4.4)
UKTh: 0 (0.0: 0.0–4.4)
UKCP: 0 (0.0: 0.0–4.4)
All: 0 (0.0: 0.0–4.4)
597,186 FR: 0 (0.0: 0.0–4.4)
DE: 0 (0.0: 0.0–4.4)
UKTh: 1 (1.2: 0.2–6.5)
UKCP: 1 (1.2: 0.2–6.5)
All: 3 (3.6: 1.2–10.1)
ADR, adverse drug reaction; All, pooled data; CAP, centrally authorized products; DE, Germany; FR, France; IMRD, IQVIA Medical Research Data; PRAC, 
Pharmacovigilance Risk Assessment Committee; RR, relative risk; UKCP, Clinical Practice Research Datalink; UKTh, IMRD-United Kingdom.
aBased on a hypothetical comparison of two proportions using a two-sided Fisher exact test with α = 0.05, power = 0.90, and equal numbers of patients exposed 
in the drug of interest and comparator cohorts.
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magnitudes of RR. This calculation provided estimates of the 
number and types of drugs that can be monitored as a function 
of actual use, minimal detectable RR, and empirically derived 
incidence rates for six adverse events.24 Based on drug exposure 
already available in the databases, they concluded that the lever-
age to perform active surveillance using healthcare data-based 
networks for signal detection is low for infrequently used drugs 
and for rare outcomes. In this evaluation, we took the real-life 
perspective of regulators needing or requiring investigations for 
drugs where there is no prior information on exposure in the 
databases.
Our study has some limitations. First, we chose three PRAC 
meetings for this evaluation in which 128 substances were discussed: 
83 CAPs and 45 NAPs. An evaluation over a longer time period (for 
example, 1 year) in which a larger number of potentially different 
medicines were considered might provide different results. However, 
the discussion of issues by the PRAC is guided by aspects linked to 
the scientific assessment of medicinal products rather than by their 
characteristics, such as therapeutic class. Analyses also considered the 
authorization status (CAP/NAP) and duration of authorization. 
There is, therefore, no strong reason to believe that a longer or an-
other period would give significantly different results. Second, the 
number of prescriptions and patients were estimated at any time in 
the lifecycle of the database until August 31, 2018, in order to re-
flect initial analyses performed to evaluate the feasibility of a study 
on specific products. We did not apply criteria for inclusion of the 
practice or study-specific restrictions in terms of medical history, pa-
tient characteristics (e.g., age and sex) or exposure time windows.25 
Applying such decisions would sharply decrease the number of 
patients eligible to enter the study population. We, therefore, con-
sider that our results represent an “optimistic” view of the relevance 
of EHDs for analyses of substances discussed by PRAC. Third, we 
used the numbers of prescriptions as a proxy for exposure and the 
number of exposed patients rather than the amount of patient-time 
of exposure to determine the density of exposure to each concerned 
substance in the databases. In fact, the numbers of prescriptions and 
patients are the measures used in initial feasibility analyses as they 
do not require assumptions of duration of prescriptions and expo-
sure time windows.25 Fourth, Tables 4 and 5, describing the number 
of patient exposures required for different event rates and different 
RRs, were required to be simplistic and intended to be indicative 
only. Many potential factors can impact on a study’s sample size 
calculation and, given limited space, we were only able to consider 
a limited number of scenarios. Other study designs would result in 
different sample size calculations and it should be noted that smaller 
RRs in particular—the likes of which are commonly encountered 
Table 5 Number and percentages of NAP substances discussed by PRAC (n = 45) for which a causal association with a 
suspected ADR could be investigated according to different background rates and strengths of association
Background 
risk Association with RR of 2.0 Association of RR of 4.0
(per number of 
patients)
Requireda number of 
patients exposed
No (%: 95% confidence interval) of 
substances that can be investigated
Requireda number 
of patients
No (%: 95% confidence interval) of 
substances that can be investigated
Very common 
(< 1/10)
282 FR: 27 (60.0: 45.5–73.0)
DE: 32 (71.1: 56.6–82.3)
UKTh: 30 (66.7: 52.1–78.6)
UKCP: 30 (66.7: 52.1–78.6)
All: 37 (82.2: 68.7–90.7)
47 FR: 29 (64.4: 49.8–76.8)
DE: 36 (80.0: 66.2–89.1)
UKTh: 31 (68.9: 54.3–80.5)
UKCP: 31 (68.9: 54.3–80.5)
All: 40 (88.9: 76.5–95.2)
Common 
(1/100)
3,220 FR: 23 (51.1: 37.0–65.0)
DE: 26 (57.8: 43.3–71.0)
UKTh: 26 (57.8: 43.3–71.0)
UKCP: 27 (60.0: 45.5–73.0)
All: 33 (73.3: 59.0–84.0)
585 FR: 26 (57.8: 43.3–71.0)
DE: 31 (68.9: 54.3–80.5)
UKTh: 29 (64.4: 49.8–76.8)
UKCP: 29 (64.4: 49.8–76.8)
All: 36 (80.0: 66.2–89.1)
Uncommon 
(1/1,000)
32,601 FR: 12 (26.7: 16.0–41.0)
DE: 21 (46.7: 32.9–60.9)
UKTh: 22 (48.9: 35.0–63.0)
UKCP: 22 (48.9: 35.0–63.0)
All: 27 (60.0: 45.5–73.0)
5,960 FR: 22 (48.9: 35.0–63.0)
DE: 25 (55.6: 41.2–69.1)
UKTh: 26 (57.8: 43.3–71.0)
UKCP: 26 (57.8: 43.3–71.0)
All: 32 (71.1: 56.6–82.3)
Rare 
(1/10,000)
326,417 FR: 2 (4.4: 1.2–14.8)
DE: 6 (13.3: 6.3–26.2)
UKTh: 11 (24.4: 14.2–38.7)
UKCP: 11 (24.4: 14.2–38.7)
All: 18 (40.0: 27.0–54.5)
59,708 FR: 8 (17.8: 9.3–31.3)
DE: 19 (42.2: 29.0–56.7)
UKTh: 21 (46.7: 32.9–60.9)
UKCP: 21 (46.7: 32.9–60.9)
All: 26 (57.8: 43.3–71.0)
Very rare 
(1/100,000)
3,264,571 FR: 0 (0.0: 0.0–7.9)
DE: 0 (0.0: 0.0–7.9)
UKTh: 0 (0.0: 0.0–7.9)
UKCP: 1 (2.2: 0.4–11.6)
All: 5 (11.1: 4.8–23.5)
597,186 FR: 1 (2.2: 0.4–11.6)
DE: 5 (11.1: 4.8–23.5)
UKTh: 8 (17.8: 9.3–31.3)
UKCP: 8 (17.8: 9.3–31.3)
All: 13 (28.9: 17.7–43.4)
ADR, adverse drug reaction; All, pooled data; CAP, centrally authorized products; DE, Germany; FR, France; IMRD, IQVIA Medical Research Data; PRAC, 
Pharmacovigilance Risk Assessment Committee; RR, relative risk; UKCP, Clinical Practice Research Datalink; UKTh, IMRD-United Kingdom.
aBased on a hypothetical comparison of two proportions using a two-sided Fisher exact test with α = 0.05, power = 0.90 and equal numbers of patients exposed 
in the drug of interest and comparator cohorts.
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when considering the safety of medicines—would require greater 
numbers to allow a meaningful analysis. Finally, we did not give con-
sideration to the regulatory context outside Europe or to databases 
held outside Europe as this was thought to be outside the scope of 
our study.
Primary EHDs are a unique resource of information on the 
use of medicines in the community. This study has shown that 
to be of use to regulatory bodies, such as PRAC and EMA, they 
may need to be complemented by other data sources for some 
types of products and especially CAPs that may be prescribed by 
specialists. Such alternative datasets may be associated with their 
own limitations. Claims databases may cover an entire popula-
tion in a region or country but contain less medical information 
on indication for treatments and possible clinical outcomes of 
these treatments. Record linkage systems allow the possibility 
of combining a wealth of data relating to prescriptions, clinical 
information, and hospital records typically based on a pseu-
do-anonymized deterministic patient identifier. However, much 
secondary care prescribing is not captured electronically and the 
pooling of several databases in this way raises other concerns, 
for example, those relating to data protection, and the potential 
to identify and compile data on individual patients. Solutions 
to such issues exist, for example, the Information Governance 
frameworks that exist in Scandinavia and elsewhere in the UK 
sources, but these can make access to such data more restrictive 
and limit the potential output of any analyses. The use of multi-
database networks (possibly incorporating the use of a common 
data model) has been advocated,10,21–23 but there is currently no 
system that allows easy and rapid in-house access to such net-
works in Europe. It should be noted that the three countries 
contributing to our analysis (France, Germany, and the United 
Kingdom) have a greater number of medicinal products available, 
have some of the shortest times between authorization and active 
marketing, and have some of the best availability of both orphan 
and oncologic therapies in the European Union.26 Interestingly, 
all three counties have well-established Health Technology 
Assessment procedure and it is reassuring to note that this results 
in high early uptake of newly authorized medicines.
In conclusion, this work assessed the extent to which medic-
inal substances discussed at PRAC over a 3-month period was 
covered in three in-house and one well-established third-party 
primary care databases. We found NAPs were better covered 
than CAPs, presumably because the latter tend to be more ad-
vanced therapies, which are typically administered in a spe-
cialized rather than a primary care setting. Newer medicinal 
substances were less well covered, as were medicinal substances 
for orphan conditions. To enable better informed regulatory de-
cisions on the safety of medicines, the capture of patient-level 
secondary care prescribing should be a priority in the future. 
Regulators should consider using a range of data sources collect-
ing data from different settings to capture a comprehensive pic-
ture of the use of medicines in clinical practice.
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